The market for first-time financing in biotech and life sciences has been challenging, with NVCA/ PwC Moneytree reporting “bottom quartile” venture investment for five of the last eight quarters. Making matters worse, sequestration has decreased the amount of grants, leaving many emerging companies searching for angel investors to fill the gap. With the SEC’s lift on the ban of general solicitation to accredited investors, and the emergence of regulation D compliant crowdfunding platforms—crowdfinance will be a part of many emerging companies funding strategies. Veteran healthcare investment banker David Loucks, CEO of Healthios Exchange, has executed over half a trillion in healthcare transactions. He will walk attendees through the changing landscape of healthcare finance, discussing how crowdfunding will impact the industry and outlining the critical steps that life science and biotech companies need to take to ensure they do not become so-called "orphans." - See more at: http://panelpicker.sxsw.com/vote/23015#sthash.8DMRAVgS.dpuf
As you may know SXSW is extremely competitive with less than 10% of panel submitted being
selected. With social voting being 30% of the overall process it is critical to get votes to speak at this prestigious event. If you have a panel please send me the links so I can vote for you. If you could do me a favor and vote for my panel below as well that would be huge.
Below is a link to the panel to vote.
http://panelpicker.sxsw.com/vote/23015
Please join HealthiosXchange, the premiere investment marketplace dedicated exclusively to the global healthcare industry employing Crowdfunding as the cornerstone of a new funding
paradigm, by clicking http://www.healthiosxchange.com/signup?ref=3